Hiv prep, inj, cabotegravir
Products billed under this code include Apretude.
Payment limit per 1 mg, by effective quarter, 4Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Apretude.
Payment limit per 1 mg, by effective quarter, 4Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Apretude | VIIV HEALTHCARE | 49702-0264-23 | 600 | $4,366.80 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $7.278 | −$0.016 | 1 mg | Hiv prep, inj, cabotegravir | v1, posted September 17, 2026 |
| 3Q26 | $7.294 | +$0.149 | 1 mg | Hiv prep, inj, cabotegravir | v1, posted September 15, 2026 |
| 2Q26 | $7.145 | −$0.002 | 1 mg | Hiv prep, inj, cabotegravir | v1, posted September 15, 2026 |
| 1Q26 | $7.147 | +$0.127 | 1 mg | Hiv prep, inj, cabotegravir | v1, posted September 15, 2026 |
| 4Q25 | $7.02 | −$0.013 | 1 mg | Hiv prep, inj, cabotegravir | v1, posted September 8, 2026 |
| 3Q25 | $7.033 | +$0.146 | 1 mg | Hiv prep, inj, cabotegravir | v1, posted March 10, 2026 |
| 2Q25 | $6.887 | −$0.005 | 1 mg | Hiv prep, inj, cabotegravir | v1, posted March 10, 2026 |
| 1Q25 | $6.892 | – | 1 mg | Hiv prep, inj, cabotegravir | v1, posted December 19, 2025 |
| 4Q24 | N/A | – | 1 mg | Hiv prep, inj, cabotegravir | v1, posted June 11, 2025 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.